莫沙必利及妈咪爱防治早产儿喂养不耐受的疗效评价

The efficacy of mosapride and Medilac-Vita in treating preterm neonates with feeding intolerance

目的:研究莫沙必利及妈咪爱防治早产儿胃肠喂养不耐受疗效。方法:2004～2005年住院早产儿107例(未给药组),未给予莫沙必利及妈咪爱预防早产儿喂养不耐受;2006～2008年住院早产儿260例(给药组),入院后即给予莫沙必利及妈咪爱预防早产儿喂养不耐受。观察2组早产儿喂养不耐受发生率及喂养不耐受患儿恢复出生体重时间及达到全胃肠道喂养时间。结果:给药组、未给药组发生喂养不耐受分别为65例、38例,发病率分别为24.07%、35.51%;喂养不耐受患儿恢复出生体重时间分别为(11.17±3.87)d、(12.92±3.91)d,达到全胃肠道喂养时间分别为(9.05±3.26)d、(11.76±6.28)d;2组差异均有统计学意义(P<0.01)。结论:莫沙必利及妈咪爱可有效防治早产儿喂养不耐受。

Objective：To observe the efficacy of mosapride and Medilac-Vita in treating preterm neonates with feeding intolerance. Methods ： One hundred and seven preterm neonates in hospital from Jan. 2004 to Dec. 2005 were treated as control group. The other 260 preterm neonates in hospital from Jan. 2006 to Dec. 2008 feeding with Mosapride and Medilac-Vitad to prevent feeding intolerance were regarded as treated group. The incidences of feeding intolerance in the two groups were observed. The time to reach full enteral feeding and the time to reach the birth weight in the preterm neonates with feeding intolerance were recorded. Results： Sixty five preterm neonates emerged feeding intolerance in treated group, the incidence was 24.07%. In these 65 cases, the time to reach the birth weight was （ 11.17±3.87） d and the time to reach full enteral feeding was （ 9.05±3.26） d. Thirty-eight preterm neonates emerged feeding intolerance in control group, the incidence was 35.51%. In the 38 cases, the time to reach full enteral feeding was （ 11.76± 6.28 ） d, the time to reach the birth weight was（ 12.92±3.91 ）d. Compared with the treated group, the difference was conspicuous. Conclusions： Mosapride and Medilae-Vita show definite effect in preventing and treating preterm neonates with feeding intolerance.